Table 5. Relative risk of cardiovascular events with preferential and selective COX-2 inhibitors compared to controls in a meta-analysis (McGettigan and Henry).

	Preferential and selective inhibitors of COX-2
	Meloxicam	Celecoxib	Rofecoxib ≤ 25 mg/day	Rofecoxib ˃ 25 mg/day	Rofecoxib combined
Case-control studies	1.25(1.00-1.55)	1.01(0.90-1.13)	1.21(1.08-1.36)	1.89(1.43-2.51)	1.31(1.18-1.46)
Cohort studies	--	1.22(0.69-2.16)	1.51(0.73-3.13)	2.46(1.29-4.71)	1.53(0.68-3.44)
Case-control and cohort studies combined	1.25(1.00-1.55)	1.06(0.91-1.23)	1.33(1.00-1.79)	2.19(1.64-2.91)	1.35(1.15-1.59)